March 11, 2016 - More Treatment Options for NSCLC Patients with ROS1+ Gene Mutation

In March 2016, the U.S. Food and Drug Administration approved the first and only drug – crizotinib (also known as Xalkori) – to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors express the ROS1+ mutation. For NSCLC patients with ROS1+ mutation, crizotinib has stopped the growth and spread of their cancer.

Read the entire article